My guess is 2/3 of the reduction is due to patent expirations and 1/3 to general downsizing and increased emphasis on specialty rather then primary-care drugs.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.